RCKT

Rocket is a late-stage but pre-revenue gene-therapy company: FY2025 product revenue was $0.00, the fifth straight year of zero, against a -$223M net loss and -$190M of operating cash burn. There is no business here yet in the fundamental sense — only a pipeline and a cash clock. The balance sheet is the disqualifier: cash and equivalents fell 52.6% to just $77.6M while the company burned roughly $190M in the year. On that run-rate the existing cash does not fund even half of another year, and management's own MD&A concedes it 'may need to raise additional funding, which may not be available on acceptable terms, or at all,' and that it 'will continue to incur losses for the foreseeable future.' The July 2025 restructuring — a ~30% workforce cut aimed at trimming 12-month opex ~25% — extends runway but is itself an admission the prior burn was unsustainable, and total assets already collapsed 37.4% YoY to $330M with stockholders' equity down 40.2%.

The forward picture is dominated by a single binary event. The company has re-focused its entire strategy on responding to the FDA's Complete Response Letter (CRL) for KRESLADI, its lead candidate, while de-prioritizing the FA and PKD programs. A CRL means the FDA has already declined to approve the drug as submitted; the entire near-term thesis now rests on whether Rocket can adequately answer the agency for an 'exceptionally small' ultra-rare patient population — a market management itself describes as tiny. The pivot to an earlier-stage AAV cardiovascular platform pushes the next real value inflection years out and through additional trials and BLAs that are not yet filed.